Lumeon

Belkins
Lumeon is driving real change in today’s complex healthcare system. With our industry-leading Lumeon Care Pathway Management (CPM) platform and suite of solutions, we enable healthcare organizations to automate systems and processes, bringing together the full potential of their organization to deliver high performance, team-centered healthcare.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

CURI BIO CLOSES $10M SERIES A IN OVERSUBSCRIBED ROUND

Curi Bio Inc. | December 30, 2021

news image

Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced the second closing of a $10 million oversubscribed Series A financing. New investors include UTC Investment and DS Asset Management, joining current Curi Bio investor and Series A lead Dynamk Capital. The investment will be used to scale Curi’s existing business and accelerate the development of its innovative engineered tissue analysis platforms, including its Mantarray™ platform.
Read More

ANIXA BIOSCIENCES TO FOCUS ON DEVELOPMENT AND EXPANSION OF ITS THERAPEUTICS AND VACCINE PORTFOLIO

Anixa Biosciences | July 03, 2020

news image

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Read More

BAY AREA BIOTECH INCUBATOR OPENS EXTENSIVE NEW LAB FACILITY, PAVING WAY FOR ENTREPRENEURS AND THEIR INNOVATION

MBC BioLabs | May 11, 2020

news image

Innovation and discovery just got easier for life science entrepreneurs as MBC BioLabs announces the opening of a 30,000 square foot building of incubator lab space in San Carlos, Calif.Built specifically as a life-science incubator space over the past 18 months, the new facility brings cutting-edge lab equipment, infrastructure and services to innovators and entrepreneurs so they can begin their discovery work virtually immediately. This is MBC BioLabs' third campus and its seco...

Read More

CELL AND GENE THERAPY

MERCK ENTERS INTO OUT-LICENSING AGREEMENT WITH BIOTECHNOLOGY COMPANY VERA THERAPEUTICS

Merck | November 11, 2020

news image

Merck, a leading science and technology company, today announced that it, through its subsidiary Ares Trading S.A., has entered into an out-licensing agreement with biotechnology company Vera Therapeutics, South San Francisco, USA, for the further development of investigational therapy atacicept. Vera Therapeutics will first prioritize to take atacicept into a Phase IIb study in IgA nephropathy (IgAN), an autoimmune kidney disease also known as "Berger's disease". "The positiv...

Read More
news image

CELL AND GENE THERAPY

CURI BIO CLOSES $10M SERIES A IN OVERSUBSCRIBED ROUND

Curi Bio Inc. | December 30, 2021

Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced the second closing of a $10 million oversubscribed Series A financing. New investors include UTC Investment and DS Asset Management, joining current Curi Bio investor and Series A lead Dynamk Capital. The investment will be used to scale Curi’s existing business and accelerate the development of its innovative engineered tissue analysis platforms, including its Mantarray™ platform.
Read More

news image

ANIXA BIOSCIENCES TO FOCUS ON DEVELOPMENT AND EXPANSION OF ITS THERAPEUTICS AND VACCINE PORTFOLIO

Anixa Biosciences | July 03, 2020

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Read More
news image

BAY AREA BIOTECH INCUBATOR OPENS EXTENSIVE NEW LAB FACILITY, PAVING WAY FOR ENTREPRENEURS AND THEIR INNOVATION

MBC BioLabs | May 11, 2020

Innovation and discovery just got easier for life science entrepreneurs as MBC BioLabs announces the opening of a 30,000 square foot building of incubator lab space in San Carlos, Calif.Built specifically as a life-science incubator space over the past 18 months, the new facility brings cutting-edge lab equipment, infrastructure and services to innovators and entrepreneurs so they can begin their discovery work virtually immediately. This is MBC BioLabs' third campus and its seco...

Read More
news image

CELL AND GENE THERAPY

MERCK ENTERS INTO OUT-LICENSING AGREEMENT WITH BIOTECHNOLOGY COMPANY VERA THERAPEUTICS

Merck | November 11, 2020

Merck, a leading science and technology company, today announced that it, through its subsidiary Ares Trading S.A., has entered into an out-licensing agreement with biotechnology company Vera Therapeutics, South San Francisco, USA, for the further development of investigational therapy atacicept. Vera Therapeutics will first prioritize to take atacicept into a Phase IIb study in IgA nephropathy (IgAN), an autoimmune kidney disease also known as "Berger's disease". "The positiv...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us